gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Polymorphism of IL-1 α, IL-1 β and IL-10 in patients with advanced ovarian cancer

Meeting Abstract

  • corresponding author presenting/speaker Elena Ioana Braicu - Universität für Medizin und Pharmazie Iuliu Hatieganu, Cluj-Napoca, Rumänien, Berlin, Deutschland
  • Cristina Pirvulescu - Gynäkologie und Geburtshilfe Universitätsklinikum, Campus-Virchow Berlin
  • Alexandru Mustea - Gynäkologie und Geburtshilfe Universitätsklinikum, Campus-Virchow Berlin
  • Dominique Könsgen - Gynäkologie und Geburtshilfe Universitätsklinikum, Campus-Virchow Berlin
  • Jalid Sehouli - Gynäkologie und Geburtshilfe Universitätsklinikum, Campus-Virchow Berlin
  • Werner Lichtenegger - Gynäkologie und Geburtshilfe Universitätsklinikum, Campus-Virchow Berlin

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO357

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk467.shtml

Veröffentlicht: 20. März 2006

© 2006 Braicu et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Several studies have been done in order to clarify the modalities in which tumors escape the immune surveillance. An important role in the development of the malignant disease is attributed to the cytokine network. IL-1 and IL-10 are supposed to be critically involved in the ovarian carcinogenesis. This study was performed to investigate the influence of polymorphisms of IL-1α, IL-1β and IL-10 gene on the occurrence of ovarian cancer.

Methods: In a prospective, monocentric, case-control study we genotyped 147 patients with OC and 129 patients with no history of malignancies (CG) for polymorphisms of the IL-1 gene (IL-1A –889T/C and IL-1B –511C/T) and IL-10 gene (IL-10 -1082G/A, -819C/T and -592C/A). Genomic DNA fragments were amplified by PCR and the allele sequence was obtained by pyrosequencing. DNA samples were obtained from tumor bank ovarian cancer (TOC).

Results: Allelic frequencies did not differ between OC and CG. In the OC group, the investigated polymorphisms did not correlate with any of the conventional clinical factors, except for the -819 and -592 IL-10 polymorphism and the postoperative residual tumor. The presence of C/C allele in -819 and -592 positions were correlated with a longer disease free and overall survival time. In multivariate models, there was no correlation between any polymorphism and disease-free and overall survival. Only postoperative residual tumor and ascites volume were independent prognostic factors for poor overall survival.

Conclusion: We investigated IL-1 and Il-10 gene polymorphisms in ovarian cancer but the allelic variation within the IL-1 and Il-10 gene clusters did not differ between ovarian cancer patients and healthy women in our study. IL-10 promoter polymorphism may be related with the ability to perform radical surgery and it also influences the disease free and overall survival. IL-10 might play an important role in the natural history of ovarian cancer. Large case-number studies are necessary in the future to evaluate the potential influence of IL-1 and IL-10 gene cluster polymorphism in ovarian carcinogenesis.